Exenatide: What the Evidence Actually Shows

Exenatide holds a real, checkable distinction none of the other GLP-1 drugs in this corpus can claim: it was the first one. Byetta (exenatide) was approved by FDA on April 28, 2005 — confirmed directly against openFDA's Drugs@FDA database — seven years before liraglutide's own first approval and nearly two decades before tirzepatide². It's also structurally distinct from everything else covered here: exenatide is a synthetic version of exendin-4, a peptide first identified in the saliva of the Gila monster, sharing only partial sequence overlap with human GLP-1 rather than being a chemically modified version of the human hormone the way liraglutide, semaglutide, and dulaglutide all are. This article covers that real approval history, a genuine reformulation story (twice-daily immediate-release vs. once-weekly extended-release, tested directly head-to-head), and — because the task behind this article specifically asked for it — a precise, live-checked answer to what's actually still on the market today, rather than an assumption either way.

The real approval history, and where exenatide came from

Byetta was approved under NDA021773 on April 28, 2005, as a twice-daily subcutaneous injection, an adjunct to diet and exercise for adults with type 2 diabetes². The pivotal trial behind that approval, a 30-week, triple-blind, placebo-controlled study in 377 sulfonylurea-treated patients, found HbA1c fell 0.86 percentage points on the 10mcg twice-daily dose versus a 0.12-point increase on placebo (adjusted P<0.001), with a modest 1.6kg weight loss at the higher dose (P<0.05 vs. placebo) and no severe hypoglycemia observed¹. Exenatide's own origin is genuinely unusual among approved drugs: it's a synthetic version of exendin-4, a peptide isolated from the venomous saliva of the Gila monster lizard, discovered because the animal's saliva triggers a prolonged, blood-glucose-lowering response — the real biological basis researchers built on to develop the first GLP-1-class diabetes drug.

A real reformulation: twice-daily versus once-weekly, tested head-to-head

Exenatide's regulatory history includes a genuine second act. Seven years after Byetta's original approval, an extended-release, once-weekly formulation — Bydureon — was approved under a separate application (NDA022200, January 27, 2012), filed as a "New Dosage Form"³. Unlike Byetta's ready-to-use pen, Bydureon's original formulation required the patient to reconstitute a lyophilized powder with a provided diluent before injecting — a real, genuine difference in how the two exenatide products were actually used, not just how often. The two formulations were tested directly against each other, not compared across separate trials: DURATION-1, a 30-week, randomized, non-inferiority trial in 295 patients, gave one group once-weekly extended-release exenatide 2mg and the other twice-daily exenatide 10mcg⁴. The once-weekly formulation didn't just match the twice-daily one — it significantly outperformed it. HbA1c fell 1.9 percentage points with once-weekly dosing versus 1.5 points with twice-daily (95% CI -0.54% to -0.12%, p=0.0023), and significantly more patients on the once-weekly formulation reached target HbA1c of 7.0% or below (77% vs. 61%, p=0.0039)⁴. That's a real, statistically meaningful result worth stating precisely rather than rounding into "equally effective, just more convenient" — the extended-release reformulation was the better-performing product on its own primary endpoint, in the trial designed specifically to compare the two head-to-head.

What's actually still on the market — checked live, not assumed

This is the question this article was built to answer precisely, because assuming either "exenatide is still widely marketed under Byetta" or "exenatide has been pulled from the market entirely" would both be wrong. A live openFDA check of every application containing exenatide as an active ingredient finds a genuinely mixed picture:

Byetta itself — the original twice-daily brand — carries a "marketing_status" of "Discontinued" for both of its approved strengths in FDA's own current Drugs@FDA record². Bydureon and Bydureon Pen — the once-weekly extended-release products — are likewise both listed as "Discontinued" under their own application (NDA022200)³. This research pass separately searched for Bydureon BCise, the once-weekly autoinjector reformulation, across four independent query attempts on two different federal databases; none returned a matching record, so this article does not assert a specific approval or discontinuation date for that particular product — a genuine gap in what a live check could confirm today, reported honestly rather than filled in from memory.

What is confirmed, and matters most for a reader asking "can I still get exenatide": a generic version of the original twice-daily formulation is currently active and prescribable. Amneal Pharmaceuticals' ANDA206697, an FDA-approved generic equivalent of Byetta at the identical two strengths (300mcg/1.2mL and 600mcg/2.4mL), was approved November 19, 2024 and carries an active "Prescription" marketing status today². So: the original brand-name products (Byetta, Bydureon, Bydureon Pen) have all been discontinued for commercial reasons — this research found no safety basis for any of those discontinuations, and Byetta's own label was actively maintained with supplements for two decades before that status changed — but exenatide the molecule is not off the market. A reader can still be prescribed it, just as a generic rather than under either original brand name.

The safety picture — genuinely different from the rest of this corpus

One real distinction worth stating plainly: Byetta's current FDA label carries no boxed warning at all⁵ — unlike liraglutide, semaglutide, dulaglutide, and (per its own label) orforglipron, none of which have that specific class-wide thyroid C-cell tumor precaution attached to exenatide. That's consistent with exenatide's different structural origin: it isn't a modified version of human GLP-1 the way the acylated, longer-acting drugs are, and the rodent thyroid-tumor signal behind the other drugs' boxed warnings has not been reported for exenatide in the same way. Exenatide's own label does carry real warnings worth knowing regardless: acute pancreatitis (a class-wide finding, "has been observed in patients treated with GLP-1 receptor agonists, including BYETTA"), hypoglycemia risk when combined with insulin secretagogues or insulin, acute kidney injury risk from GI-related volume depletion, and a specific instruction that pens must never be shared between patients even with the needle changed⁵. None of these are boxed warnings, but they're real, current label language worth reading directly rather than assuming exenatide's absent thyroid warning means an absent safety profile altogether.

Why this site doesn't have an exenatide reconstitution calculator

The currently active exenatide product — the Amneal generic of Byetta — ships as a ready-to-use pre-filled pen, with no reconstitution step, confirmed directly from its own FDA product listing. Bydureon's original formulation genuinely did require reconstituting a lyophilized powder with a provided diluent before injection — a real difference from Byetta's pen — but Bydureon itself is confirmed discontinued above, so there is no currently-marketed reconstituted exenatide product on the market to build a calculator against. A direct check of "sells.ts" and "other-compounds.ts" found zero mentions of exenatide, Byetta, or Bydureon among this site's reviewed providers. No "/calculator/exenatide" page is built.

What this means if you're considering it

Exenatide is a real, historically significant, FDA-approved drug — the original GLP-1 receptor agonist, approved in 2005, seven years before liraglutide and nearly two decades before tirzepatide. Its once-weekly reformulation genuinely outperformed the original twice-daily version in a real head-to-head trial. Both of the original brand-name products (Byetta and Bydureon/Bydureon Pen) are confirmed discontinued in FDA's own current records, for reasons this research found no safety basis for — but a generic, twice-daily version approved in late 2024 keeps the molecule itself on the market today. It carries no thyroid boxed warning, a genuine structural distinction from the newer, chemically modified GLP-1 drugs covered elsewhere on this site. For how it compares to the drug class it founded, our liraglutide evidence review and our dulaglutide evidence review cover the later, longer-acting drugs exenatide's own approval made possible.